CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 6,083,488	$ 6,523,817	$ 11,476,034	$ 12,606,984
General and administrative	2,092,758	3,028,042	4,350,761	5,788,250
Total operating expenses	8,176,246	9,551,859	15,826,795	18,395,234
Operating loss	(8,176,246)	(9,551,859)	(15,826,795)	(18,395,234)
Gain on derivative instruments	0	2,195	0	366,791
Other non-operating losses			0	(30,793)
Interest expense, net	(159,063)	(273,828)	(311,852)	(546,862)
Other expense	(7,500)	0	(57,671)
Net loss	(8,342,809)	(9,823,492)	(16,196,318)	(18,606,098)
Modification of warrants			(171,552)	0
Net loss available to common shareholders	$ (8,342,809)	$ (9,823,492)	$ (16,367,870)	$ (18,606,098)
Net loss per common share - basic and diluted	$ (0.19)	$ (0.23)	$ (0.38)	$ (0.43)
Weighted average common shares outstanding - basic and diluted	43,588,381	43,122,671	43,513,571	43,100,070